Article
Oncology
Xiaoqi Li, Mansi Gulati, Alaina C. Larson, Joyce C. Solheim, Maneesh Jain, Sushil Kumar, Surinder K. Batra
Summary: Pancreatic cancer has high mortality and limited response to immunotherapy due to the immuno-suppressive tumor microenvironment and high expression of immune checkpoints. Combining immunotherapy with modulators of the tumor microenvironment may lead to the development of new therapeutic regimens.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Immunology
Zihan Zhao, Siyang Liu, Rui Sun, Wenjie Zhu, Yulin Zhang, Tianyao Liu, Tianhang Li, Ning Jiang, Hongqian Guo, Rong Yang
Summary: Bladder cancer is a highly malignant tumor with limited improvement in prognosis and survival rates. Immune checkpoint inhibitors have revolutionized the treatment of bladder cancer, but their clinical application is limited by low response rates. This study investigated the combination of oxaliplatin and anti-PD-1 inhibitor in bladder cancer mouse models and found that this combination therapy was more efficient than medication alone.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Rosalynd Upton, Allison Banuelos, Dongdong Feng, Tanuka Biswas, Kevin Kao, Kelly McKenna, Stephen Willingham, Po Yi Ho, Benyamin Rosental, Michal Caspi Tal, Tal Raveh, Jens-Peter Volkmer, Mark D. Pegram, Irving L. Weissman
Summary: Trastuzumab, a targeted anti-HER2 monoclonal antibody, is effective for early-stage HER2(+) breast cancer but resistance often develops in advanced-stage patients. Combining trastuzumab with anti-CD47 immunotherapy shows promising results in inhibiting the growth of ADCC-tolerant HER2(+) breast cancers.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Nanoscience & Nanotechnology
Xiaoning Lin, Rong Huang, Yanlin Huang, Kai Wang, Heng Li, Yiheng Bao, Chaohui Wu, Yi Zhang, Xinhua Tian, Xiaomin Wang
Summary: Sonodynamic therapy (SDT) and checkpoint blockade immunotherapy are promising treatments for solid cancers, but their efficacy can be limited. By combining SDT with immunotherapy and nanoparticles, such as TiO2, Chlorin e6, and CpG ODN, a multifunctional nanosonosensitizer was developed to enhance antitumor efficacy of anti-PD-L1 antibody. The nanosonosensitizers not only effectively inhibited tumor growth but also stimulated immune responses, leading to efficient primary tumor growth inhibition and inhibition of distant tumors by inducing a strong tumor-specific immune response. This innovative approach offers a promising strategy for treating malignant tumors.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2021)
Article
Immunology
Hui Peng, Lijin Li, Chong Zuo, Michael Y. Chen, Xiuli Zhang, Nancy B. Myers, Graham D. Hogg, David G. DeNardo, S. Peter Goedegebuure, William G. Hawkins, William E. Gillanders
Summary: Preclinical and human translational studies suggest that combining neoantigen vaccines with therapies targeting the PD-1 and TIGIT signaling pathways may improve the treatment efficacy in patients with PDAC.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Guiyuan Chen, Xiangxia Li, Rui Li, Kecheng Wu, Zhouhang Lei, Ruike Dai, Kyle Roche, Andrew Z. Wang, Yuanzeng Min
Summary: Researchers hypothesized that treating cancer cells with ultrahigh doses of chemotherapeutics in vitro could artificially enhance the immunogenicity, thereby improving chemoimmunotherapy.
Article
Oncology
Enliang Li, Xing Huang, Gang Zhang, Tingbo Liang
Summary: This study systematically investigated the potential effectiveness of a novel pancreatic cancer immunotherapy targeting RTKs, and revealed the function of MET in PD-L1 regulation as well as the combined therapeutic efficacy of MET and PD-L1 in pancreatic cancer. Results showed that MET is a pancreatic cancer-specific RTK significantly associated with prognosis and positively correlated with PD-L1 levels. The study also demonstrated that MET deficiency facilitates lymphocyte infiltration into pancreatic tumors and verified significant benefits of combining MET inhibition with PD-1/PD-L1 blockage in mouse models of pancreatic cancer.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Chemistry, Multidisciplinary
Chao He, Luodan Yu, Heliang Yao, Yu Chen, Yongqiang Hao
Summary: A BG@NbSiR scaffold has been developed to effectively treat bone metastasis of breast cancer by activating immune response, suppressing metastases, preventing tumor relapses, and promoting osteogenesis. Single-cell sequencing has been used to identify critical factors responding to this scaffold-based therapy, providing insights into underlying therapeutic mechanisms.
ADVANCED FUNCTIONAL MATERIALS
(2021)
Article
Oncology
Jing Yang, Shilin Zhao, Jing Wang, Quanhu Sheng, Qi Liu, Yu Shyr
Summary: Cancer-Immu is a comprehensive platform that integrates various omics data and clinical phenotypes to explore immunogenomic connections. It provides easy access to data and helps researchers translate omics datasets into biological insights and clinical applications.
Article
Engineering, Biomedical
Qianwen Yu, Xian Tang, Wei Zhao, Yue Qiu, Jiao He, Dandan Wan, Jianping Li, Xuhui Wang, Xuan He, Yayuan Liu, Man Li, Zhirong Zhang, Qin He
Summary: The combination of mild hyperthermia and immune checkpoint blockade treatment effectively suppressed tumor growth and metastasis; size-adjustable nanoparticles have great potential in improving cancer treatment outcomes.
ACTA BIOMATERIALIA
(2021)
Article
Immunology
Yaping Chen, Hao Huang, Yuan Li, Wenlu Xiao, Yingting Liu, Rongzhang Chen, Yulan Zhu, Xiao Zheng, Changping Wu, Lujun Chen
Summary: Combination immunotherapy based on immune checkpoint inhibitors (ICIs) has shown great success in cancer treatment, and the combination of ablation and immunotherapy has potential for the treatment of liver metastasis of colorectal cancer (CRC). The expression of TIGIT was up-regulated after microwave ablation (MWA), and the combination of MWA and TIGIT blockade significantly promoted the expansion and functions of CD8(+) tumor-infiltrating lymphocytes (TILs) and reshaped myeloid cells in the tumor microenvironment (TME).
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Chemistry, Multidisciplinary
Elham Masoumi, Sahar Tahaghoghi-Hajghorbani, Leila Jafarzadeh, Mohammad-Javad Sanaei, Atieh Pourbagheri-Sigaroodi, Davood Bashash
Summary: This review provides an overview of the current research status of immune checkpoint blockades in breast cancer and discusses the efficacy and limitations of ICB therapy in breast cancer treatment.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Medicine, Research & Experimental
Dong Shao, Yaping Chen, Hao Huang, Yingting Liu, Junjun Chen, Dawei Zhu, Xiao Zheng, Lujun Chen, Jingting Jiang
Summary: This study demonstrates that the combination therapy of LAG3 blockade and microwave ablation (MWA) is a unique treatment strategy for certain solid tumors, which can alter the tumor microenvironment and extend survival.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Medicine, Research & Experimental
Yujeong Moon, Man Kyu Shim, Jiwoong Choi, Suah Yang, Jinseong Kim, Wan Su Yun, Hanhee Cho, Jung Yeon Park, Yongju Kim, Joon-Kyung Seong, Kwangmeyung Kim
Summary: In this study, the researchers propose a new strategy to enhance cancer immunotherapy by using anti-PD-L1 peptide-conjugated prodrug nanoparticles (PD-NPs). The PD-NPs are taken up by cancer cells and release the drug, resulting in the disruption of immune-suppressing pathways and the enhancement of T lymphocyte immune responses. The results show that PD-NPs accumulate in tumor tissues and recruit a large amount of immune cells, leading to effective antitumor effects. This strategy has the potential to overcome the toxicity and low response rate issues in current cancer immunotherapy.
Article
Immunology
Qi-jie Zhang, Jiao-chen Luan, Le-bin Song, Rong Cong, Cheng-jian Ji, Xiang Zhou, Jia-dong Xia, Ning-hong Song
Summary: The study found no difference in efficacy between elderly and young patients in most cancer types, except for melanoma patients receiving anti-PD-1 therapy. Elderly patients showed higher treatment response rate and more favorable prognosis in certain cancer types, potentially attributed to their high mutational properties. This suggests that modulating immune function could be beneficial to immunotherapy in elderly patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Sebastian Havervall, Henry Ng, August Jernbom Falk, Nina Greilert-Norin, Anna Manberg, Ulrika Marking, Ida Lauren, Lena Gabrielsson, Ann-Christin Salomonsson, Katherina Aguilera, Martha Kihlgren, Maja Mansson, Axel Rosell, Cecilia Hellstrom, Eni Andersson, Jennie Olofsson, Lovisa Skoglund, Jamil Yousef, Elisa Pin, Martin Lord, Mikael Aberg, My Hedhammar, Hanna Tegel, Pierre Donnes, Mia Phillipson, Peter Nilsson, Jonas Klingstrom, Sara Mangsbo, Sophia Hober, Charlotte Thalin
Summary: Emerging data suggests detectable immune responses can last for months after SARS-CoV-2 infection or vaccination, but the degree and duration of protection against reinfection remains uncertain. A study on healthcare workers and COVID-19 patients found that the majority of individuals tested positive for anti-spike IgG antibodies remained positive for at least 8 months, with a significantly reduced risk of reinfection up to 9 months following asymptomatic to mild COVID-19.
JOURNAL OF INTERNAL MEDICINE
(2022)
Article
Multidisciplinary Sciences
Sebastian Havervall, August Jernbom Falk, Jonas Klingstrom, Henry Ng, Nina Greilert-Norin, Lena Gabrielsson, Ann-Christin Salomonsson, Eva Isaksson, Ann-Sofie Rudberg, Cecilia Hellstrom, Eni Andersson, Jennie Olofsson, Lovisa Skoglund, Jamil Yousef, Elisa Pin, Wanda Christ, Mikaela Olausson, My Hedhammar, Hanna Tegel, Sara Mangsbo, Mia Phillipson, Anna Manberg, Sophia Hober, Peter Nilsson, Charlotte Thalin
Summary: Current serological assays for SARS-CoV-2 generate inconsistent results and the longitudinal characteristics of antibodies targeting different antigens after asymptomatic or mild COVID-19 have not been established. This cohort study involving healthcare workers found that antibodies against the SARS-CoV-2 spike antigen remained detectable in 96% of participants at least four months after infection, even if they had no or mild symptoms. The study also confirmed virus neutralization capacity in 91% of participants at least four months after infection.
Article
Oncology
Espen Basmo Ellingsen, Elin Aamdal, Tormod Guren, Wolfgang Lilleby, Paal F. Brunsvig, Sara M. Mangsbo, Steinar Aamdal, Eivind Hovig, Nadia Mensali, Gustav Gaudernack, Else Marit Inderberg
Summary: Therapeutic cancer vaccine UV1 has been studied in three phase I/IIa clinical trials for malignant melanoma, non-small cell lung cancer, and prostate cancer. The vaccine induced measurable T cell responses in 78.4% of treated patients, with superior response kinetics observed in the melanoma study. Long-term immunomonitoring showed persistent telomerase peptide-specific immune responses lasting up to 7.5 years after initial vaccination.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Immunology
Ulrika Marking, Sebastian Havervall, Nina Greilert-Norin, Henry Ng, Kim Blom, Peter Nilsson, Mia Phillipson, Sophia Hober, Charlotta Nilsson, Sara Mangsbo, Wanda Christ, Jonas Klingstrom, Max Gordon, Mikael Aberg, Charlotte Thalin
Summary: Heterologous primary SARS-CoV-2 vaccination with ChAd and BNT elicits a stronger initial immune response compared to homologous vaccination with ChAd, particularly in terms of antibody response. However, although the differences in humoral responses remain over 6 months, the difference in SARS-CoV-2 specific T cell responses are no longer significant three months after vaccination.
Article
Medicine, General & Internal
Andreas Tolf, Anna Wiberg, Malin Muller, Faisal Hayat Nazir, Ivan Pavlovic, Ida Lauren, Sara Mangsbo, Joachim Burman
Summary: For an optimal vaccine response from tozinameran, rituximab-treated patients with multiple sclerosis should be vaccinated as soon as possible, with rituximab treatment delayed until B-cell counts have reached at least 40/mu L. An additional vaccination with tozinameran should be considered at that point.
Article
Immunology
Ida Lauren, Sebastian Havervall, Henry Ng, Martin Lord, Aleksandra Pettke, Nina Greilert-Norin, Lena Gabrielsson, Aikaterini Chourlia, Catarina Amoedo-Leite, Vijay S. Josyula, Mohamed Eltahir, Iliana Kerzeli, August J. Falk, Jonathan Hober, Wanda Christ, Anna Wiberg, My Hedhammar, Hanna Tegel, Joachim Burman, Feifei Xu, Elisa Pin, Anna Manberg, Jonas Klingstrom, Gustaf Christoffersson, Sophia Hober, Peter Nilsson, Mia Philipson, Pierre Donnes, Robin Lindsay, Charlotte Thalin, Sara Mangsbo
Summary: This study investigates the correlation between symptomology and cellular immune responses post seroconversion to COVID-19. The findings demonstrate that the severity of the disease and specific COVID-19 symptoms are correlated with the magnitude of SARS-CoV-2-specific memory T cell responses. The study highlights the importance of cellular immune memory in understanding the immune response to COVID-19.
IMMUNITY INFLAMMATION AND DISEASE
(2022)
Letter
Infectious Diseases
Kim Blom, Ulrika Marking, Sebastian Havervall, Nina Greilert Norin, Max Gordon, Marina Garcia, Teghesti Tecleab, Wanda Christ, Mattias Forsell, Mia Phillipson, Peter Nilsson, Sara Mangsbo, Sophia Hober, Mikael Aberg, Jonas Klingstrom, Charlotte Thalin
LANCET INFECTIOUS DISEASES
(2022)
Article
Medicine, Research & Experimental
Espen Basmo Ellingsen, Gergana Bounova, Iliana Kerzeli, Irantzu Anzar, Donjete Simnica, Elin Aamdal, Tormod Guren, Trevor Clancy, Artur Mezheyeuski, Else Marit Inderberg, Sara M. Mangsbo, Mascha Binder, Eivind Hovig, Gustav Gaudernack
Summary: This clinical trial evaluated the efficacy of a novel therapeutic cancer vaccine, UV1, in combination with ipilimumab, in patients with metastatic melanoma. It was found that the vaccine-induced T cells had clinical responses, regardless of established predictive biomarkers for checkpoint inhibitor efficacy. The combination of UV1 vaccine and checkpoint inhibitors warrants further investigation.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Editorial Material
Biotechnology & Applied Microbiology
Sara M. Mangsbo
EXPERT OPINION ON BIOLOGICAL THERAPY
(2023)
Article
Oncology
Michelle H. Nelson, Sara Fritzell, Robert Miller, Doreen Werchau, Danielle Van Citters, Anneli Nilsson, Lynda Misher, Lill Ljung, Robert Bader, Adnan Deronic, Allison G. Chunyk, Lena Schultz, Laura A. Varas, Nadia Rose, Maria Hakansson, Jane Gross, Christina Furebring, Peter Pavlik, Anette Sundstedt, Niina Veitonmaki, Hilario J. Ramos, Anna Sall, Anna Dahlman, David Bienvenue, Laura von Schantz, Catherine J. McMahan, Maria Askmyr, Gabriela Hernandez-Hoyos, Peter Ellmark
Summary: 4-1BB is an activation-induced costimulatory receptor that enhances immune responses of activated CD8 T and natural killer cells. A bispecific antibody, ALG.APV-527, has been developed to stimulate 4-1BB function along with the tumor-associated antigen 5T4, showing potent antitumor activity and potential as a promising anticancer therapeutic for 5T4-expressing tumors.
MOLECULAR CANCER THERAPEUTICS
(2023)
Article
Biochemistry & Molecular Biology
Camilla Eriksson, Sunithi Gunasekera, Taj Muhammad, Mingshu Zhang, Ida Lauren, Sara M. Mangsbo, Martin Lord, Ulf Goransson
Summary: This study investigates the use of stable cyclic peptide scaffolds to present antigenic sequences derived from the spike protein of the SARS-CoV-2 virus. It shows that displaying epitopes on the scaffold improves reactivity and suggests diagnostic potential.
Article
Multidisciplinary Sciences
Ulrika Marking, Sebastian Havervall, Nina Greilert Norin, Oscar Bladh, Wanda Christ, Max Gordon, Henry Ng, Kim Blom, Mia Phillipson, Sara Mangsbo, Jessica J. Alm, Anna Smed-Sorensen, Peter Nilsson, Sophia Hober, Mikael Aberg, Jonas Klingstroem, Charlotte Thalin
Summary: Vaccination provides protection against severe COVID-19 caused by SARS-CoV-2 omicron, but is less effective against infection. High levels of serum antibodies are shown to be protective against infection and linked to reduced viral load and time to viral clearance. Pre-omicron SARS-CoV-2 infection is independently associated with increased protection against omicron, largely mediated by mucosal spike-specific IgA responses.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Iliana K. Kerzeli, Alexandros Kostakis, Polat Turker, Per-Uno Malmstroem, Tammer Hemdan, Artur Mezheyeuski, Douglas G. Ward, Richard T. Bryan, Ulrika Segersten, Martin Lord, Sara M. Mangsbo
Summary: In this study, plasma and urine samples from bladder cancer patients were analyzed to identify potential biomarkers. It was found that MMP7 and CCL23 levels were higher in plasma, while CD27 and CD40 levels were higher in urine. Increased levels of MMP12 in plasma were associated with shorter overall survival. Tumor-infiltrating macrophages were identified as a possible source of MMP12.
Article
Cell Biology
Hampus Andersson, Aastha Sobti, David Gomez Jimenez, Yago Pico de Coana, Sumeet Vijay Ambarkhane, Karin Hagerbrand, Karin Enell Smith, Malin Lindstedt, Peter Ellmark
Summary: CD40-targeting therapies can enhance immune activation by activating dendritic cells and repolarizing intratumoral macrophages. This study found that mitazalimab induced transient changes in the blood transcriptome, primarily due to immune activation. Furthermore, distinct patient subgroups based on transcriptomic alterations were identified.
Article
Clinical Neurology
Faisal Hayat Nazir, Anna Wiberg, Malin Mueller, Sara Mangsbo, Joachim Burman
Summary: Multiple sclerosis is a complex and heterogeneous disease that often starts as a clinically isolated syndrome. Autoantibodies play an important role in its pathogenesis, but their target has been difficult to identify. Cell-based methods have been developed as an alternative strategy for detecting autoantibodies. This study explored differences in antibody binding to oligodendroglial and neuronal cell-lines in serum and CSF samples from multiple sclerosis patients and controls, and found that the binding of immunoglobulin G from CSF to the human oligodendroglioma cell-line was the best discriminator between patients and controls, with a high sensitivity and specificity. The cell-based ELISA showed a high degree of accuracy in discriminating between multiple sclerosis patients and controls, with the disease course being the major determinant for antibody binding.
BRAIN COMMUNICATIONS
(2023)